










Dendrimer-Functionalized Shell-crosslinked Iron Oxide
Nanoparticles for In-Vivo Magnetic Resonance Imaging
of Tumors**By Xiangyang Shi,* Su He Wang,* Scott D. Swanson, Song Ge, Zhengyi Cao,
Mary E. Van Antwerp, Kevin J. Landmark, and James R. Baker, Jr.*Non-invasive diagnosis and detection of early-stage tumors
is regarded as one of the current challenges in the biomedical
sciences. Magnetic resonance (MR) imaging is a powerful,
non-invasive imaging technique because of its high spatial
resolution and tomographic capabilities. However, the signal
sensitivity of MR imaging for specific biological targets is
largely dependent on the specificity and selectivity of the ligand
used to target magnetic nanoparticles (NPs) to specific tissues.
Development of tumor-targeted magnetic NPs is necessary to
enhance the MR signal sensitivity for in-vivo tumor detection.
Various proteins such as transferrin,[1,2] anti-carcinoembryonic
antigen monoclonal antibody rch 24,[3] herceptin,[4–6] and
chlorotoxin[7] have been conjugated onto iron oxide NP
surfaces. Unfortunately, these protein ligands tend to display
immunogenecity and the biological macromolecules used are
very expensive and not available for many types of cancer,
which thereby limits their applications. One of the most widely
used cancer-targeting ligands is folic acid (FA), which targets
FA receptors (FAR) that are overexpressed in several human
carcinomas including breast, ovary, endometrium, kidney,
lung, head and neck, brain, and myeloid cancers.[8–10] Several
groups have investigated the conjugation of folic acid (FA)
onto iron oxide NPs for targeting tumor cells.[11–17] However,
many of these reports are limited to in-vitro studies. This is
largely a result of difficulties related to the in-vivo stability and[*] Dr. X. Shi, Dr. S. H. Wang, Z. Cao, M. E. Van Antwerp
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implies that a biocompatible and robust polymer coating onto
iron oxide NP surfaces may be essential for a successful in-vivo
MR imaging of a tumor.
The authors have recently embarked on the surface
modification of iron oxide NPs with dendrimers for biomedical
imaging applications. Dendrimers are a new class of highly
branched, monodispersed, and synthetic macromolecules with
well-defined structure, composition, and architecture. Den-
drimers, especially poly(amidoamine) (PAMAM) dendrimers,
have been shown to be capable of conjugating targeting
ligands, imaging agents, and drugmolecules for targeted cancer
therapeutics.[18–21] It is expected that appropriately manip-
ulating the iron oxide NP surfaces with dendrimer chemistry
may offer possibilities for sensing of various biological systems.
Early work has shown that carboxy-terminated PAMAM
dendrimers can be successfully assembled onto Fe3O4 NPs for
intracellular uptake studies.[22] However, because of the large
amount of carboxy groups on the dendrimer surface, the Fe3O4
NPs modified with FA do not show specific binding to the
FAR-expressing cells in vitro. In a previous work, it has been
shown that Fe3O4 NPs modified through an approach that
combines a layer-by-layer (LbL) self-assembly technique[23–34]
and dendrimer chemistry[18–20] can specifically target tumor
cells overexpressing FAR in vitro.[35] In these studies, a bilayer
composed of polystyrene sulfonate sodium salt (PSS) and FA-
and FI (fluorescein isothiocyanate)-functionalized PAMAM
dendrimers of generation 5 (G5.NH2-FI-FA) were assembled
onto Fe3O4 NPs through electrostatic LbL assembly, followed
by acetylation of the remaining surface amine groups of the
assembled G5 dendrimers. Unfortunately, in-vivo data show
that most of these bilayer-modified Fe3O4 NPs accumulate in
the liver of mice, which suggests that the particles lack in-vivo
stability (unpublished results). Development of a robust
polymer shell coating onto Fe3O4 is necessary to achieve a
successful in-vivo MR image of a tumor. Approaches to
accomplish this involve increasing the polymer layer thickness
and/or chemically crosslinking the polymer shells.[36–41]
Literature reports show that poly(glutamic acid) (PGA) and
poly(L-lysine) (PLL) multilayers can be successfully self-
assembled on planar substrates[42,43] and display very good
biocompatibility for implant coatings.[44] In this present study,
iron oxide NPs are assembled with multilayers of PGA and
PLL, followed by assembly with G5.NH2-FI-FA dendrimers.












Figure 1. a) Schematic representation of the procedure for fabricating multifunctional shell-crosslinked iron oxide NPs. b) A TEM image of SCIO-FA NPs.
c) A negatively phosphotungstic acid-stained TEM image of SCIO-FA NPs.
1672(1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochlor-
ide) chemistry to covalently link the hydroxy groups of iron
oxide, the carboxy groups of PGA, and the amino groups of
PLL and the dendrimers. The remaining amino groups of the
dendrimers are finally acetylated to neutralize the surface
charge (Fig. 1a). The formed shell-crosslinked iron oxide
(SCIO) NPs are characterized using zeta-potential analysis,
Fourier-transform infrared (FT-IR) spectroscopy, transmis-
sion electron microscopy (TEM), and relaxivity measure-
ments. Combined flow cytometry and in-vitro and in-vivo MR
imaging studies show that the FA-modified SCIO NPs can
specifically bind to tumor cells and an early-stage tumor model
overexpressing FAR. To our knowledge, this is the first
example of the fabrication of multifunctional iron oxide NPs
using shell-crosslinked polymer multilayers combined with
dendrimer chemistry for in-vivo MR imaging studies. The
present approach using crosslinked polymer shells to functio-
nalize Fe3O4NPs with biological ligands opens a new avenue to
fabricating various NPs for a range of in-vivo biological sensing
and therapeutic applications.
LbL self-assembly, shell crosslinking, and chemical mod-
ification of the SCIO NPs were monitored by zeta-potentialwww.advmat.de  2008 WILEY-VCH Verlag GmbHmeasurement (Table S1, Supporting Information). It is clear
that the positively charged Fe3O4 NPs become negatively
charged after PGA modification. After PLL assembly, the
Fe3O4 NPs again reverse to being positively charged. Further
PGA modification decreases the surface charge. The changes
in charge of the Fe3O4 NPs indicate the successful electrostatic
assembly of (PGA/PLL)2/PGA/G5.NH2-FI-FA multilayers.
The EDC crosslinking reaction does not result in a significant
change of the surface charge of the Fe3O4 NPs. However, after
the acetylation reaction, the zeta potentials of both (PGA/
PLL)2/PGA/G5.NHAc-FI and (PGA/PLL)2/PGA/G5.NHAc-
FI-FANPs are close to neutral because of the conversion of the
dendrimer surface amine groups to acetamide groups. This is in
sharp contrast to the findings in a previous work,[35] wherein
acetylation of dendrimer/PSS bilayer-modified Fe3O4 NPs did
not result in Fe3O4 NPs with close to a neutral charge. This is
presumably a result of the EDC crosslinking reaction, which
makes the dendrimer amines that interact with the PGA
polymer through electrostatic interaction covalently couple
with the PGA.
The fabricated SCIO NPs were characterized by TEM (Fig.












(SCIO-FA) NPs does not show significant change after the
assembly and crosslinking of the polymers and dendrimers
when compared with the pristine Fe3O4 NPs (Fig. 1b).
[22,35] A
negatively stained TEM image using phosphotungstic acid
(Fig. 1c) clearly shows that all Fe3O4 NPs are surrounded with
the bright rings of the polymer multilayers, which confirms the
successful self-assembly process. The non-targeted SCIO
(SCIO-NonFA) NPs display a morphology similar to that of
SCIO-FA NPs (images not shown). The fabricated SCIO NPs
are very stable both in aqueous solution and in a cell culture
medium for at least 6 months at Fe concentrations of up to
10mg mL1. It is worth noting that five layers of the
polyelectrolyte (PGA and PLL) were selected to deposit onto
the Fe3O4 NPs in this work. This is because the assembly of five
layers of polyelectrolytes plus one layer of G5 dendrimers is
sufficient to maintain the shape of the intact hollow polymer
capsules once the Fe3O4 core particles are removed (see below
in Fig. 2). This is also consistent with previous reports related to
the formation of polyelectrolyte multilayer capsules.[25,45] It is
likely that fewer layers of the PGA/PLL assemblymay result in
a weak stability of the SCIONPs for in-vivo applications, while
the assembly of more PGA/PLL layers might introduce issues
related to the colloidal stability of the SCIONPs as discussed in
a previous report.[35]
The EDC chemical crosslinking reaction was confirmed by
FT-IR spectrometry (Supporting Information, Fig. S1). The
absorbance of the amide bond of (PGA/PLL)2/PGA/
G5.NH2-FI-FA-modified Fe3O4 NPs increased after EDC
crosslinking when compared with the same NPs before EDC
crosslinking. Although FT-IR spectroscopy is not a very
effective approach to characterize the intensity of the amide
bond before and after shell crosslinking (because the PGA and
PLL polymers, and the dendrimers that were used themselves,
also contain many amide bonds), the FT-IR spectra qualita-
tively verify the formation of amide bonds between the
carboxy groups of PGA and the amine groups of PLL and
dendrimers. To further confirm the improvement of the
mechanical stability after EDC shell crosslinking, the mor-
phology of the polymer shells after the removal of the ironFigure 2. TEM images of (PGA/PLL)2/PGA/G5.NH2-FI-FA hollow polymer c
intact hollow polymer capsules before EDC crosslinking. b) A magnified imag
capsule indicated by a horizontal arrow. d) (PGA/PLL)2/PGA/G5.NH2-FI-FA
Adv. Mater. 2008, 20, 1671–1678  2008 WILEY-VCH Verlaoxide core particles was investigated (Fig. 2). It is clear that
before EDC crosslinking, intact hollow polymer nanocapsules
can be formed (Fig. 2a–c). Some of the capsules have a
completely empty interior (Fig. 2b), while some of the capsules
still contain iron residue as a result of incomplete removal (Fig.
2c). In sharp contrast, after EDC crosslinking, most of the
capsules formed are broken (Fig. 2d). This is presumably
because of the huge rupture force induced instantaneously by
the swelling and dissolution of iron oxide cores, which further
confirms that the mechanical stability of the SCIO NPs is
significantly improved, while the permeability of the capsules
after EDC crosslinking is decreased. This provides further
evidence to show the successful EDC crosslinking reaction.
The transverse relaxation time (T2) of water protons in an
aqueous solution of fabricated SCIO NPs was measured at
2Tesla with a Carr–Purcell–Meiboom–Gill (CPMG) pulse
sequence and the measured data were used to compute the
transverse relaxivity (r2) (the transverse relaxation rate per mM
of iron). The r2 of uncoated Fe3O4 NPs, SCIO-FA NPs, and
SCIO-NonFANPs as a function of Fe concentration are shown
in the Supporting Information (Fig. S2). The uncoated Fe3O4
NPs show the highest r2 relaxivity (r2¼ 100.4 s1mM1),
whereas the r2 relaxivities of SCIO-FA and SCIO-NonFA
NPs are somewhat reduced at 46.3 and 78.8 s1mM1,
respectively. The polymer coating onto the Fe3O4 NPs shields
water molecules from their surfaces, and causes the lower r2
relaxivity of SCIO NPs. Compared with SCIO-NonFA NPs,
the presence of the FA moieties of the SCIO-FA NPs may
significantly increase the hydrophobicity and hindrance of the
coating layers, thereby enhancing the shielding effect.[46] As a
consequence, SCIO-FA NPs exhibit a lower r2 relaxivity than
that of SCIO NPs without FA.
The cytotoxicity of the functionalized SCIO NPs was
evaluated by fluorescein diacetate (FDA) and propidium
iodide (PI) staining. Cell viability data (Supporting Informa-
tion, Fig. S3) show that the KB cells (a human epithelial
carcinoma cell line) treated by SCIO NPs with or without FA
conjugation display a similar percentage of FDA positive cells
to the KB cells treated by unmodified Fe3O4 NPs at an Feapsules after iron oxide core removal. a) (PGA/PLL)2/PGA/G5.NH2-FI-FA
e of the capsule indicated by a vertical arrow. c) A magnified image of the
hollow polymer capsules after EDC crosslinking.












Figure 3. In-vitro flow cytometric analysis of binding of SCIO NPs with KB cells and MR images of cell pellets. Dose-dependent binding of SCIO-FA and
SCIO-NonFA NPs with KB cells expressing high- (a) and low-level (b) FAR. T2 weighted spin-echo images of KB-HFAR cells incubated with functionalized
SCIO-FA and SCIO-NonFANPs with Fe concentrations of 0, 6.3, 12.5, 25.0mgmL1 c). The color change from red to blue indicates the gradual decrease of
MR signal intensity.
Table 1. T2 of KB-HFAR cells treated with functionalized Fe3O4 NPs.
Fe concentration [mgmL1] T2 [s]
SCIO-NonFA SCIO-FA
0 (PBS control) 1.16W 0.016 1.16W 0.016
6.3 0.387W 0.004 0.104W 0.005
12.5 0.105W 0.006 0.062W 0.0009
25.0 0.061W 0.0001 0.03W 0.0014
1674concentration of 0–100mgmL1. This indicates that the SCIO
NPs are biocompatible at an Fe concentration of up to
100mgmL1.
The FA and FI dyes on the modified G5 dendrimer surfaces
were used as targeting ligands and imaging molecules,
respectively. The attached FI moieties afford a flow cytometric
study of the binding of SCIO NPs with target cells. KB cells
that express both high and low levels of FAR (denoted as
KB-HFAR and KB-LFAR, respectively) were selected for the
intracellular uptake of SCIO NPs. Figure 3a and 3b illustrate
the dose-dependent cellular uptake of the binding of SCIO-FA
and SCIO-NonFA NPs. At an Fe concentration above
2.5mgmL1, KB-HFAR cells exposed to SCIO-FA NPs show
remarkably higher fluorescence signals than those treated with
SCIO-NonFA NPs without FA (Fig. 3a). With the increase of
Fe concentration, the mean fluorescence levels off. This
implies that the high affinity of FAR mediates specific uptake
of the NPs. Both SCIO-NonFA and SCIO-FA NPs display
much less uptake in KB-LFAR cells than in KB-HFAR cells,
even at an Fe concentration of up to 50mgmL1 (Fig. 3b).
However, in the studied concentration range, SCIO-FA NPs
exhibit more uptake in KB-LFAR cells than SCIO-NonFA
NPs without FA modification, which is similar to what was
observed with these cells in a previous study.[35] This is a result
of the larger number of FA moieties per SCIO-FA NP
compared with a single FA-modified dendrimer, whichwww.advmat.de  2008 WILEY-VCH Verlag GmbHfacilitates polyvalent binding, thereby significantly increasing
the binding affinity of Fe3O4 NPs to each KB-LFAR cell.
Iron oxide NPs affect theMR signal by dephasing transverse
magnetization and hence reducing the value of T2. A targeted
iron oxide NP would have a major benefit in tumor imaging by
specifically detecting tumors that overexpress the FAR. To
study the effect of the SCIO-FA NPs on tumor cells, the T2 of
KB-HFAR cells exposed to differing Fe concentrations of
SCIO-FA NPs were measured. The T2 values of KB-HFAR
cell pellets treated with SCIO-FA NPs dramatically decreased
as a function of Fe concentration (Table 1). In contrast, the
decreasing trend of T2 values as a function of Fe concentration
for the same KB cells treated with SCIO-NonFA NPs is
significantly less than that of the KB cells treated with
SCIO-FA NPs. In the T2-weighted spin-echo MR images (the












Figure 4. In-vivo MR imaging of tumor. In-vivo color maps (a) of T2-weighted MR images of mice implanted with cancer cell line KB cells, at different time
points after injection of SCIO-NonFA and SCIO-FA NPs, respectively. The color bar (from red to blue) indicates the MR signal intensity changes from high
to low. Comparison of statistically normalized histograms of the voxel intensities (whole tumor) from targeted SCIO-FA (green histogram) and
non-targeted SCIO-NonFA (red histogram) NPs at the time points of 1 h (b), 4 h (c), 8 h (d), 24 h (e), 48 h (f), and 7 days (g).MR signal intensity, which is similar to those reported based on
the intensity of the black color[4,47]) obtained using an Fe
concentration of 25mgmL1, SCIO-FA NPs significantly
diminished the signal (Fig. 3c). This suggested that SCIO-FA
NPs can specifically hamper the MR signal through
FAR-mediated binding and endocytosis.
The in-vivo MR imaging of tumors using SCIO NPs are
presented on one slice of the three-dimensional (3D) dataset
from the images acquired following the injection of eitherAdv. Mater. 2008, 20, 1671–1678  2008 WILEY-VCH Verlatargeted SCIO-FA or non-targeted SCIO-NonFA NPs (Fig.
4a). The images were colored to allow easy visualization of the
contrast changes as a function of time post-injection. The
control image was obtained from a mouse without treatment.
The tumor MR signal intensity of mice injected with SCIO-FA
NPs gradually decreases as a function of time. In sharp
contrast, the tumor MR signal intensity of mice treated with
SCIO-NonFA NPs does not decrease significantly with time












1676SCIO-FA NPs, the tumor MR signal intensity has decreased
more significantly than the signal intensity in the tumors of the
mouse treated with non-targeted SCIO-NonFA NPs and in
the control mouse. After 48 h post-injection, the difference of
the MR signal intensity of the tumors is smaller for both mice
injected with SCIO-FA and SCIO-NonFA NPs. It is worth
mentioning that the size of the colored tumors shown in Fig. 4a
may not be consistent because the T2-weighted MR images of
the mice may be taken at different positions, and the images
shown in Fig. 4a might not be in the same plane for the same
mouse. The MR intensity data from the whole tumor at
different slices were collected and used to create normalized
statistical histograms of the signal decrease for all time points
of post-injection (Fig. 4b–g). Again, it is clear that at the 24 h
post-injection time point, the targeted SCIO-FA NP-treated
tumor shows the most significant decrease of signal intensity
when compared with the tumor treated with SCIO-NonFA
NPs and the control mouse. After 48 h post-injection, the
differences between the tumor MR signal intensity of the
targeted and non-targeted NPs becomes smaller. The differ-
ences in the MR signal intensity of several major organs (such
as the liver, kidney, muscle, and tumor) of different mice at 24 h
after injection of the SCIONPs were also compared in order to
gain an understanding of the biodistribution of SCIO NPs (Fig.
S4, Supporting Information). It is clear that for SCIO-FA
NP-treated mice, the MR signal intensity of the tumor, kidney,
and muscle decreased more significantly when compared with
the control mice and the SCIO-NonFA NP-treated mice. This
suggests that the SCIO-FA NP-treated mice show more iron
oxide uptake in the three different tissues than the SCIO-
NonFA NP-treated mice. However, the MR signal intensity of
the liver follows the order of: control mice> SCIO-FA
NP-treated mice> SCIO-NonFA NP-treated mice. This sug-
gests that SCIO-NonFA NP-treated mice display more uptake
of iron oxide in the liver than the SCIO-FANP-treated mice. It
is very important to note that the selection of the PGA and
PLL polymer pair for the in-vivo MR imaging studies may be
extended to other polymer pairs that can be chemically
crosslinked. However, the polymer pairs must be biocompa-
tible. Unpublished data show that the SCIO NPs prepared
using a poly(acrylic acid)/poly(allylamine hydrochloride)
multilayer assembly under similar conditions do not allow
for effective MR imaging of tumors in vivo at 24 h. As a matter
of fact, a slight decrease of MR signal in tumors for
FA-targeted NPs (as compared with non-targeted NPs without
FA modification) can only be observed after 7 days. It implies
that the polymer pairs used to assemble Fe3O4 NPs must be
biocompatible in order to avoid significant macrophage
cellular uptake.
In summary, a novel approach has been developed that
uniquely combines the LbL self-assembly method with
dendrimer chemistry to fabricate targeted shell-crosslinked
iron oxide NPs for MR imaging of tumors. The fabricated
SCIO NPs are water-soluble, stable, and biocompatible. Both
in-vitro and in-vivo MR imaging studies show that the SCIO
NPs with FA modification (SCIO-FA NPs) can specificallywww.advmat.de  2008 WILEY-VCH Verlag GmbHtarget tumor cells that overexpress FAR and an
FAR-expressing tumor model with a volume as small as
0.60 0.15 cm3, respectively. This approach to the functiona-
lization of magnetic NPs may be applied to other small
targetingmolecules (e.g., peptides and growth factors), thereby
providing a general cost-effective approach for MR detection
of various biological systems.Experimental
Materials: Ethylenediamine core amine-terminated PAMAM den-
drimers of generation 5 (G5.NH2) with a polydispersity index of less
than 1.08 were purchased fromDendritech (Midland, MI). FA, FI, acetic
anhydride, triethylamine, ferric chloride hexahydrate (FeCl36H2O>
99%), ferrous chloride tetrahydrate (FeCl24H2O> 99%), sodium
hydroxide, 2-(N-morpholino)ethane sulphonic acid (MES), 1-ethyl-
3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC), hydro-
chloric acid, and all the other chemicals and solvents were purchased
from Aldrich (St. Louis, MO) and used as received. Poly(L-glutamic
acid) (PGA) sodium salt (Mw¼ 15 000–50 000 gmol1) and poly
(L-lysine) (PLL) hydrobromide (Mw¼ 15 000–30 000 gmol1) were
from Sigma. Iron oxide NPs, and FI- and FA-functionalized generation
5 (G5.NH2-FI-FA) PAMAM dendrimers were synthesized and
characterized according to previously published methods [35]. FI-
functionalized G5 dendrimers (G5.NH2-FI) without FA conjugation
were used as control. PGA, PLL, and dendrimers were dissolved in
phosphate-buffered saline (PBS) solution (pH 7.4) that contained 0.5 M
NaCl at a concentration of 1mgmL1. KB cells were from American
Type Tissue Collection (ATCC, Rockville, Maryland). Penicillin,
streptomycin, fetal bovine calf serum (FBS), fluorescein diacetate
(FDA), and propidium iodide (PI) were purchased from Sigma (St.
Louis, MO). Trypsin-EDTA, Dulbecco’s PBS, and RPMI 1640
medium (with or without FA), and bovine serum albumin were
obtained from GIBCO-BRL (Gaithersburg, MD).
Fabrication of Multifunctional Shell-crosslinked Iron Oxide
NPs: The procedure used to fabricate multifunctional SCIO NPs is
shown in Fig. 1a. The LbL assembly of oppositely charged PGA and
PLL was performed according to the literature. [27] Briefly, a solution
of Fe3O4 NPs (5mg in 0.5mLwater, diameter 8.4 1.4 nm, synthesized
and characterized according to previously published methods [35]) was
added to 1mL of a PGA solution (1mgmL1, pH 7.4 PBS buffer that
contained 0.5M NaCl) with occasional shaking. After adsorption of
PGA for 20min, the suspensionwas centrifuged at 8000 rpm for 10min.
The supernatant was then carefully removed, and the coated Fe3O4
NPs were washed by three alternate cycles of centrifuging and
resuspending the particles in pure water. PLL solution (1mL,
1mgmL1, pH 7.4 PBS buffer that contained 0.5 M NaCl) was then
added into the PGA-modified Fe3O4 NP suspension and purified in the
same manner. These steps were repeated until 5 layers, (PGA/
PLL)2PGA, were deposited onto the Fe3O4 NPs. The outermost layer
of FI- and FA-functionalized generation 5 PAMAM dendrimers
(G5.NH2-FI-FA) (1mgmL
1, pH 7.4 PBS buffer that contained 0.5 M
NaCl) was then deposited in the same way and the final (PGA/
PLL)2PGA/G5.NH2-FI-FA-modified Fe3O4 NPs were dispersed into
50 103 M MES buffer (pH¼ 5.5) and EDC (12–18mg) was added to
crosslink the hydroxy groups of the Fe3O4 NPs and the amino groups of
PLL and the dendrimers with the carboxy groups of PGA. Themixture
was shaken overnight, followed by three cycles of centrifugation/
redispersion (in water) to remove residual reactants. The SCIO NPs
with FAmodification (SCIO-FANPs) were subjected to an acetylation
reaction to neutralize the remaining amine groups of the G5.NH2-
FI-FA dendrimers, using a procedure described elsewhere [48]. The
control SCIO NPs (Fe3O4/(PGA/PLL)2/PGA/G5.NHAc-FI NPs)
without FA conjugation (SCIO-NonFA NPs) were prepared in the












FI-modified amine-terminated G5 dendrimers (G5.NH2-FI) used were
prepared and characterized according to a previous report [35].
General Characterization Methods: FT-IR spectra were acquired
using a Perkin Elmer Spectrum GX FTIR system. Dry particles were
mixed with milled KBr crystals and the samples were pressed as pellets
before measurement. The iron concentration of the Fe3O4 NPs before
and after surface modification was determined by inductively coupled
plasma–optical emission spectroscopy (ICP-OES) using a Perkin–
Elmer Optima 2000 DV. The surface potential of functionalized Fe3O4
NPs was measured by a Malvern Zetasizer Nano ZS model ZEN3600
(Worcestershire, UK) equipped with a standard 633nm laser. The size
and morphology of the Fe3O4 NPs were characterized by a Philips
CM-100 TEM equipped with a Hamamatsu Digital Camera
ORCA-HR operated using AMT software (Advanced Microscopy
Techniques Corp, Danver, MA). The operation voltage was kept at
60 kV. TEM samples were prepared by deposition of a dilute particle
suspension (5mL) onto a carbon-coated copper grid and were air-dried
before measurement. Stained specimens were prepared by depositing
the sample solutions on the grid and inverting the grid on a drop of
aqueous phosphotungstic acid solution. In order to investigate the
morphology of the polymer hollow capsules before and after EDC
crosslinking, the SCIO NPs were exposed to 3 M HCl to erode the
Fe3O4 core particles. MR relaxometry of SCIO NPs was performed
using a 2.0T Varian Unity/Inova system (Palo Alto, CA) using
home-built RF coils. SCIO NPs were diluted in water at variable
concentrations. ForMR relaxometrymeasurements, SCIONPs (1mL)
were placed in 1.5mL Eppendorf vials. T2 relaxation times were
measured using a standard CPMG pulse sequence (TR¼ 2000 ms, TE
range 30–960ms, 32 echoes, FOV¼ 134 67mm2, matrix 128 64,
slice thickness 10mm, BW¼ 40, NEX¼ 3). T2 relaxation times were
calculated by a linear fit of the logarithmic ROI signal amplitudes
versus TE. TheT2 relaxivities (r2) were determined by a linear fit of the
inverse relaxation times as a function of the Fe concentration used.
KB Cell Culture: The KB cells were continuously grown in two
24-well plates, one in FA-free medium and the other in regular RPMI
1640 medium supplemented with penicillin (100 unitsmL1), strepto-
mycin (100mgmL1), 10% heat-inactivated fetal bovine calf serum
(FBS), and 2.5 106 M FA. The cells grown in FA-free medium
express high-level FAR, while the cells grown in FA-containing
medium express low-level FAR.
Determination of Cell Viability: Cell viability wasmeasured byFDA
and PI staining. FDA stains live cells, while PI stains dead cells. The
stained cells were quantified by flow cytometry as described byKillinger
et al. . [49] Briefly, 2 105 KB cells per well were seeded into a 24-well
plate and incubated with 0–100mgmL1 of unmodified Fe3O4 NPs,
SCIO-NonFA NPs, and SCIO-FA NPs for 24h at 37 8C. Ten thousand
cells were acquired from each sample for flow cytometric analysis.
Determination of Binding Affinity by Flow Cytometry: Approximately
2 105 cells per well were seeded in 24-well plates the day before the
experiments. An hour before initiating an experiment, the cells were
rinsed three times with serum-free and FA-deficient RPMI 1640
medium. SCIO-NonFA and SCIO-FA NPs were added at Fe
concentrations of 0–50mg mL1. After 1 h of incubation at 37 8C, KB
cells with both high- and low-level FARwere trypsinized and suspended
in PBS that contained 0.1% bovine serum albumin, and then analyzed
using a Coulter EPICS-XL MCL Beckman–Coulter flow cytometer.
The FL1-fluorescence of 10 000 cells was measured, and the mean
fluorescence of gated viable cells was quantified using Expo32 software
(Beckman–Coulter, Miami, FL).
In-vitro MR Relaxometry and Imaging: KB-HFAR cells (5 106)
were incubated with SCIO-NonFA and SCIO-FA NPs with Fe
concentrations of 6.3, 12.5, and 25mgmL1 for 30min in an ice bath.
Live cells were usually cultured with a complete medium at 37 8C. For
the MR imaging studies, live cells were trypsinized and suspended in
PBS (instead of cell culture medium) and incubated with NPs. The cells
were then washed with PBS buffer three times. The cells were
centrifuged to prepare pellets for MR imaging according to the
procedure described in a previous report [35].Adv. Mater. 2008, 20, 1671–1678  2008 WILEY-VCH VerlaTumor Model: A murine tumor model was established in NOD
C.B-17 SCID mice using human KB tumor cells over-expressing FAR
as described previously [18]. When the tumor nodules had reached a
volume of 0.60 0.15 cm3 (approximately 3 weeks post-injection), the
animals were randomly allocated into control, SCIO-NonFA, and
SCIO-FA groups. SCIO-FA and SCIO-NonFANPs were delivered via
the tail vein in 0.1mL of saline at 12.4mg Fe per mouse, respectively.
Two-dimensional (2D) and three-dimensional (3D) MR images were
obtained both before and after administration of either imaging agent
at time points of hours 1, 4, 8, 24, 48, and day 7 after injection.
In-vivo MR Imaging: The MR imaging probe, constructed
specifically for these studies, was based on an Alderman–Grant slotted
cylinder design (length 10 cm, OD 4.5 cm). The probe was made with
polycarbonate tubing, copper tape, and ATC and Johanson capacitors.
Following induced anesthesia, the mouse to be imaged was placed
inside a second polycarbonate tube (ID 2.6 cm). This second tube was
then inserted into the MR probe, which allowed easy animal
positioning and restricted the mouse MR imaging studies to a region
of homogeneous RF field. MR imaging was performed on a 2T Varian
Unity/Inova system equipped with Acustar S180 gradients. At each
time point for each animal, 2D and 3D gradient-echo MR images were
obtained. Two sets of interleaved, 2D gradient-echo images were
acquired with a 2mm slice thickness, TR/TE 100/5ms, flip angle 458, in
plane resolution 390mm, and 8 averages. The total time to acquire the
2D images was 2.5min. The 3D gradient-echo images were acquired
with a TR/TE of 20/4ms, a flip angle of 208, isotropic voxel resolution of
390mm, and 4 averages. Imaging time for the 3D dataset was 5.5min.
The 3D gradient echo pulse sequence was chosen to provide isotropic
spatial resolution,minimizemotion artifacts, and generateT2-weighted
MR images. See Supporting Information for details.
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